Non-Alcoholic Steatohepatitis Treatment Market Size, Share & Trends Analysis Report By Drug Type (Obeticholic Acid, Lanifibranor, Semaglutide, Resmetirom, Aramchol, Cenicriviroc), By End-use, By Region, And Segment Forecasts, 2022 - 2030

Non-Alcoholic Steatohepatitis Treatment Market Growth & Trends

The global non-alcoholic steatohepatitis treatment market size is expected to reach USD 15.95 billion by 2030, according to a new report by Grand View Research, Inc. The industry is projected to expand at a CAGR of 39.2% from 2022 to 2030. The non-alcoholic steatohepatitis (NASH) treatment market is primarily driven by the launch of drugs such as Novo Nordisk's Ozempic, Intercept's Ocaliva, and Inventiva's lanifibranor, among others.

The NASH treatment market has major unmet needs owing to factors such as the unavailability of approved drugs, high disease burden, and complex diagnostic procedures. Currently, the market is dominated by off-label drugs such as Pioglitazone and Vitamin E. These are widely prescribed drugs in this space globally. However, to address the unmet opportunity, key market players are heavily investing in R&D activities to develop novel therapeutics for NASH treatment. Currently, there are more than 50 pipeline candidates.

Some of the late-stage pipeline candidates expected to launch during the forecast period include Inventiva Pharma's Lanifibranor, Intercept Pharmaceuticals' Obeticholic acid, Galmed Pharmaceuticals Ltd.'s Aramchol, Novo Nordisk A/S's Semaglutide, and Madrigal Pharmaceuticals, Inc.'s Resmetirom. Among these, Intercept Pharmaceuticals's Obeticholic Acid (OCA), and Madrigal Pharmaceuticals, Inc.'s Resmetirom, are the most looked upon drugs and are expected to enter comparatively earlier than other pipeline candidates.

Research studies reveal that non-alcoholic steatohepatitis is strongly associated with obesity and diabetes. Research studies show that around 80% of NASH patients are obese. In countries such as the U.S., the obesity prevalence is as high as 42%, according to the latest 2021 statistics by CDC. In addition, countries such as the U.S. and Japan account for the highest prevalence of non-alcoholic steatohepatitis globally, and these countries also have a high burden of obesity and diabetes. All such factors will fuel the NASH treatment market throughout the forecast period.

Strategic initiatives by pharma giants and supportive regulatory authority policies such as fast track designation are further expected to accelerate the market growth. In May 2022, Pfizer, Inc.'s Ervogastat/Clesacostat Combination therapy received fast track designation. This is one of the potential drug combinations for the treatment of non-alcoholic steatohepatitis. Such drug designation boosts the clinical trial process for drugs.

Liver biopsy is the gold standard for the diagnosis of non-alcoholic steatohepatitis. The invasive nature of this diagnostics test limits its usage to only symptomatic cases, and as a result, the global average diagnostic rate for NASH is around 20%. The unavailability of biomarkers-based non-invasive tests for the diagnosis of non-alcoholic steatohepatitis is expected to impede the market growth.

Non-Alcoholic Steatohepatitis Treatment Market Report Highlights

  • Vitamin E and Pioglitazone (Off-label) acted as the lone contributor with 100% share to the market in 2021. This can be attributed to the unavailability of approved drugs in the market
  • The retail and specialty pharmacies segment held a share of 63.8% in 2021. Retail and specialty pharmacies are more compatible with chronic diseases such as NASH, where the patients are more commonly associated with homecare settings
  • North America dominated the overall NASH treatment space in terms of revenue. This can be attributed to increased disease awareness, better healthcare facilities, and comparatively higher treatment rate than in other regions
Please note The report will be delivered in 2-8 business days upon order notification.


Chapter 1 Methodology and Scope
1.1 Market Segmentation and Scope
1.1.1 Segment scope
1.1.2 Regional scope
1.1.3 Estimates and forecast timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased database
1.3.2 GVR's internal database
1.3.3 Secondary sources
1.3.4 Primary research
1.3.5 Details of primary research
1.4 Information or Data Analysis
1.4.1 Data analysis models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Approach: Commodity Flow Approach
1.7 Research Assumptions
1.8 List of Secondary Sources
1.9 List of Abbreviations
1.10 Objectives
1.10.1 Objective 1
1.10.2 Objective 2
1.10.3 Objective 3
1.10.4 Objective 4
Chapter 2 Executive Summary
2.1 Market Summary
Chapter 3 Non-Alcoholic steatohepatitis treatment market Variables, Trends, and Scope
3.1 Penetration and Growth Prospect Mapping
3.2 Regulatory Landscape
3.3 Industry Analysis - Porter's Five Forces
3.4 PESTEL Analysis (Political & Legal, Economic, and Technological)
3.5 Epidemiology Analysis
3.6 Unmet need analysis
3.7 Pipeline Analysis, by Phase
Chapter 4 Non-Alcoholic steatohepatitis treatment market: Segment Analysis, by Drug Type, 2018 - 2030 (USD Million)
4.1 Non-Alcoholic steatohepatitis treatment market: Drug Type Movement Analysis
4.2 Vitamin E and Pioglitazone
4.2.1 Vitamin E and Pioglitazone Market, 2018 - 2030 (USD Million)
4.3 Obeticholic Acid (OCA)
4.3.1 Obeticholic Acid (OCA) market, 2018 - 2030 (USD Million)
4.4 Lanifibranor
4.4.1 Lanifibranor Market, 2018 - 2030 (USD Million)
4.5 Semaglutide
4.5.1 Semaglutide Market, 2018 - 2030 (USD Million)
4.6 Resmetirom
4.6.1 Resmetirom Market, 2018 - 2030 (USD Million)
4.7 Aramchol
4.7.1 Aramchol Market, 2018 - 2030 (USD Million)
4.8 Cenicriviroc
4.8.1 Cenicriviroc Market, 2018 - 2030 (USD Million)
4.9 Others
4.9.1 Others Market, 2018 - 2030 (USD Million)
Chapter 5 Non-Alcoholic steatohepatitis treatment market: Segment Analysis, by End-use, 2018 - 2030 (USD Million)
5.1 Non-Alcoholic steatohepatitis treatment market: End-use Movement Analysis
5.2 Hospital Pharmacies
5.2.1 Hospital Pharmacies Market, 2018 - 2030 (USD Million)
5.3 Retail and Specialty Pharmacies
5.3.1 Retail and Specialty Pharmacies Market, 2018 - 2030 (USD Million)
5.4 Others
5.4.1 Others Market, 2018 - 2030 (USD Million)
Chapter 6 Non-Alcoholic steatohepatitis treatment market: Segment Analysis, By Region, 2018 - 2030 (USD Million)
6.1 Definition & Scope
6.2 Regional Market Share Analysis, 2021 & 2030
6.3 Regional Market Snapshot
6.4 Market Size, & Forecasts, Revenue and Trend Analysis, 2021 to 2030
6.4.1 North America
6.4.1.1 North America market estimates and forecast, 2018 - 2030 (USD Million)
6.4.1.2 U.S.
6.4.1.2.1 U.S. Non-Alcoholic steatohepatitis treatment market, 2018 - 2030 (USD Million)
6.4.1.3 Canada
6.4.1.3.1 Canada Non-Alcoholic steatohepatitis treatment market, 2018 - 2030 (USD Million)
6.4.2 Europe
6.4.2.1 Europe Non-Alcoholic steatohepatitis treatment market, 2018 - 2030 (USD Million)
6.4.2.2 UK
6.4.2.2.1 UK Non-Alcoholic steatohepatitis treatment market, 2018 - 2030 (USD Million)
6.4.2.3 Germany
6.4.2.3.1 Germany Non-Alcoholic steatohepatitis treatment market, 2018 - 2030 (USD Million)
6.4.2.4 Spain
6.4.2.4.1 Spain Non-Alcoholic steatohepatitis treatment market, 2018 - 2030 (USD Million)
6.4.2.5 France
6.4.2.5.1 France Non-Alcoholic steatohepatitis treatment market, 2018 - 2030 (USD Million)
6.4.2.6 Italy
6.4.2.6.1 Italy Non-Alcoholic steatohepatitis treatment market, 2018 - 2030 (USD Million)
6.4.3 Asia Pacific
6.4.3.1 Asia Pacific Non-Alcoholic steatohepatitis treatment market, 2018 - 2030 (USD Million)
6.4.3.2 Japan
6.4.3.2.1 Japan Non-Alcoholic steatohepatitis treatment market, 2018 - 2030 (USD Million)
6.4.3.3 China
6.4.3.3.1 China Non-Alcoholic steatohepatitis treatment market, 2018 - 2030 (USD Million)
6.4.3.4 India
6.4.3.4.1 India Non-Alcoholic steatohepatitis treatment market, 2018 - 2030 (USD Million)
6.4.3.5 South Korea
6.4.3.5.1 South Korea Non-Alcoholic steatohepatitis treatment market, 2018 - 2030 (USD Million)
6.4.3.6 Australia
6.4.3.6.1 Australia Non-Alcoholic steatohepatitis treatment market, 2018 - 2030 (USD Million)
6.4.4 Latin America
6.4.4.1 Latin America Non-Alcoholic steatohepatitis treatment market, 2018 - 2030 (USD Million)
6.4.4.2 Brazil
6.4.4.2.1 Brazil Non-Alcoholic steatohepatitis treatment market, 2018 - 2030 (USD Million)
6.4.4.3 Mexico
6.4.4.3.1 Mexico Non-Alcoholic steatohepatitis treatment market, 2018 - 2030 (USD Million)
6.4.4.4 Argentina
6.4.4.4.1 Argentina Non-Alcoholic steatohepatitis treatment market, 2018 - 2030 (USD Million)
6.4.5 MEA
6.4.5.1 MEA Non-Alcoholic steatohepatitis treatment market, 2018 - 2030 (USD Million)
6.4.5.2 South Africa
6.4.5.2.1 South Africa Non-Alcoholic steatohepatitis treatment market, 2018 - 2030 (USD Million)
6.4.5.3 Saudi Arabia
6.4.5.3.1 Saudi Arabia Non-Alcoholic steatohepatitis treatment market, 2018 - 2030 (USD Million)
6.4.5.4 UAE
6.4.5.4.1 UAE Non-Alcoholic steatohepatitis treatment market, 2018 - 2030 (USD Million)
Chapter 7 Non-Alcoholic steatohepatitis treatment market: Competitive Analysis
7.1 Recent Developments and Impact Analysis, by Key Market Participants
7.1.1 New Product Launches
7.1.2 Mergers and Acquisitions
7.1.3 Partnerships and Strategic Collaboration
7.2 Company Categorization
7.2.1 Innovators
7.2.2 Market Leaders
7.3 Vendor Landscape
7.3.1 List of key distributors and channel partners
7.4 Key Customers
7.5 Key Company Market Share Analysis, 2021
7.6 Public Companies
7.6.1 Company market position analysis
7.6.2 Competitive Dashboard Analysis
7.6.1.1 Market Differentiators
7.7 Private Companies
7.7.1 List of key emerging companies
7.7.2 Regional Network Map
7.8 Company Profiles
7.8.1 Intercept Pharmaceuticals
7.8.1.1 Company overview
7.8.1.2 Financial performance
7.8.1.3 Product benchmarking
7.8.1.4 Strategic initiatives
7.8.2 Galmed Pharmaceuticals
7.8.2.1 Company overview
7.8.2.2 Financial performance
7.8.2.3 Product benchmarking
7.8.3 Inventiva Pharma
7.8.3.1 Company overview
7.8.3.2 Financial performance
7.8.3.3 Product benchmarking
7.8.4 Novo Nordisk A/S
7.8.4.1 Company overview
7.8.4.2 Financial Performance
7.8.4.3 Product Benchmarking
7.8.4.4 Strategic initiatives
7.8.5 AbbVie Inc.
7.8.5.1 Company overview
7.8.5.3 Financial Performance
7.8.5.4 Product benchmarking
7.8.5.5 Strategic initiatives
7.8.6 Galectin Therapeutics Inc.
7.8.6.1 Company overview
7.8.6.2 Financial performance
7.8.6.3 Product benchmarking
7.8.6.4 Strategic initiatives
7.8.7 Madrigal Pharmaceuticals
7.8.7.1 Company overview
7.8.7.2 Product benchmarking
7.8.8 NGM Biopharmaceuticals Inc.
7.8.8.1 Company overview
7.8.8.2 Financial performance
7.8.8.3 Product benchmarking
7.8.8.4 Strategic initiatives
7.8.9 Bristol Myers Squibb
7.8.9.1 Company overview
7.8.9.2 Financial performance
7.8.9.3 Product benchmarking
7.8.9.4 Strategic initiatives
7.8.10 Novo Nordisk A/S
7.8.10.1 Company overview
7.8.10.2 Financial performance
7.8.10.3 Product benchmarking
7.8.10.4 Strategic initiatives
7.8.11 Gilead Sciences Inc
7.8.11.1 Company overview
7.8.11.2 Financial performance
7.8.11.3 Product benchmarking
7.8.11.4 Strategic initiatives 

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings